Do Billionaires Chase Coleman and David Tepper Know Something About UnitedHealth Stock That Wall Street Doesn't?

UnitedHealth reported Q1 2026 results that beat expectations, with revenue and earnings ahead of estimates and the medical cost ratio improving 90 bps to 83.9%. Despite that, Chase Coleman sold about 17% of his UNH stake, David Tepper cut exposure by 55%, and Berkshire Hathaway fully exited in Q1, highlighting mixed investor positioning. Wall Street remains bullish, with 22 of 28 analysts rating the stock a buy or strong buy, supported by improving cost trends and long-term demographic tailwinds.

Analysis

The key market read is not that UNH is “cheap” or “expensive,” but that the stock is transitioning from a de-risking story to a prove-it story. When a large-cap insurer’s cost trend inflects, the first derivative matters more than the absolute number: a 90 bp improvement in medical cost ratio can translate into outsized EPS leverage if sustained for multiple quarters, because operating leverage in managed care is high once utilization normalizes.

The second-order effect is that capital is likely rotating within healthcare rather than out of it. If UNH can re-rate on cleaner cost discipline, the relative losers are peers with weaker scale and less pricing power, especially those more exposed to MA rate volatility or with narrower underwriting buffers. On the other side, if the DOJ process drags or rate-setting disappoints, the market will punish duration risk in the entire health-insurance complex because investors will extrapolate that UNH’s size no longer immunizes it from regulatory pressure.

The consensus is probably underpricing timing risk. Wall Street can be right on 12-month fundamentals while still missing a 1-2 quarter air pocket if investors wait for sustained evidence that cost trends are truly benign. The billionaire selling matters less as a fundamental signal than as a positioning signal: crowded holders may be using the name as a defensive compounder, so any disappointment can force a fast de-grossing. That creates a setup where the stock can grind higher over months, but with sharp drawdown risk around earnings, regulatory headlines, or any re-acceleration in utilization.

The contrarian angle is that the best risk/reward may not be outright long UNH, but owning the recovery while hedging the event risk. If the market has become too sensitive to litigation and reimbursement noise, the earnings path could still surprise to the upside; if not, the multiple can compress even on acceptable results. The asymmetry is favorable only if investors can survive headline volatility and avoid overpaying for a clean story too early.

Key Decisions for Investors

• Initiate a staged long UNH position over 2-4 weeks rather than all at once; size for a 5-8% drawdown around headlines, targeting 15-20% upside if cost trends hold through the next earnings cycle.
• Pair long UNH / short a weaker managed-care peer basket for 3-6 months to isolate execution alpha versus sector beta; this works best if the thesis is cost discipline, not broad healthcare multiple expansion.
• Buy UNH downside protection into the next earnings or DOJ milestone window: 3-6 month puts or put spreads to cap litigation and utilization surprise risk while keeping upside exposure.
• If UNH rallies >10% without a second confirming quarter, take profits on one-third to one-half of the position; the market may be front-running a single data point rather than a durable rerating.
• Avoid chasing the move in insurer peers until UNH’s cost curve is validated; a confirmed UNH rebound is a negative signal for relative-value shorts in higher-risk managed care names.